Literature DB >> 10508312

Safety of magnetic resonance imaging contrast agents.

F G Shellock1, E Kanal.   

Abstract

Many of the MR examinations performed in the world each year are accompanied by administration of one of these frequently used intravenous contrast agents: Magnevist, Omniscan, and ProHance. Accordingly, MR practitioners must understand the basic pharmacokinetics, side effects, and the potential for adverse events for these contrast agents. Additionally, MR practitioners must know how to manage side effects and adverse events that may occur in association with the administration of contrast agents. Notably, the use of MR imaging contrast agents in special patient populations must be understood. This article discusses each of these important issues.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10508312     DOI: 10.1002/(sici)1522-2586(199909)10:3<477::aid-jmri33>3.0.co;2-e

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  58 in total

1.  Multicenter phase-II trial of safety and efficacy of NC100150 for steady-state contrast-enhanced peripheral magnetic resonance angiography.

Authors:  Tim Leiner; Kai Yiu J A M Ho; Vincent B Ho; Georg Bongartz; Willem P T M Mali; Wenche Rasch; Jos M A van Engelshoven
Journal:  Eur Radiol       Date:  2003-01-18       Impact factor: 5.315

Review 2.  Perspectives for preventive screening with total body MRI.

Authors:  Susanne C Ladd; Mark E Ladd
Journal:  Eur Radiol       Date:  2007-06-05       Impact factor: 5.315

Review 3.  Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.

Authors:  Aaron Joseph L Villaraza; Ambika Bumb; Martin W Brechbiel
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 4.  Molecular imaging with nanoparticles: giant roles for dwarf actors.

Authors:  Paul Debbage; Werner Jaschke
Journal:  Histochem Cell Biol       Date:  2008-09-30       Impact factor: 4.304

5.  Micro-engineered local field control for high-sensitivity multispectral MRI.

Authors:  Gary Zabow; Stephen Dodd; John Moreland; Alan Koretsky
Journal:  Nature       Date:  2008-06-19       Impact factor: 49.962

6.  Apparition of iodinated contrast agents in twin neonatal gastrointestinal tracts after maternal contrast-enhanced computed tomography.

Authors:  Hiroki Kato; Masayuki Kanematsu; Kenji E Orii; Masahiro Morimoto; Zenichiro Kato; Naomi Kondo
Journal:  Jpn J Radiol       Date:  2011-09-01       Impact factor: 2.374

Review 7.  Contrast-enhanced pulmonary MRA for the primary diagnosis of pulmonary embolism: current state of the art and future directions.

Authors:  Donald G Benson; Mark L Schiebler; Michael D Repplinger; Christopher J François; Thomas M Grist; Scott B Reeder; Scott K Nagle
Journal:  Br J Radiol       Date:  2017-04-12       Impact factor: 3.039

8.  Optimization of Contrast-to-Tissue Ratio Through Pulse Windowing in Dual-Frequency "Acoustic Angiography" Imaging.

Authors:  Brooks D Lindsey; Sarah E Shelton; Paul A Dayton
Journal:  Ultrasound Med Biol       Date:  2015-03-25       Impact factor: 2.998

9.  Stabilized porous liposomes with encapsulated Gd-labeled dextran as a highly efficient MRI contrast agent.

Authors:  Zhiliang Cheng; Ajlan Al Zaki; Ian W Jones; Henry K Hall; Craig A Aspinwall; Andrew Tsourkas
Journal:  Chem Commun (Camb)       Date:  2014-01-24       Impact factor: 6.222

10.  Gadolinium-conjugated dendrimer nanoclusters as a tumor-targeted T1 magnetic resonance imaging contrast agent.

Authors:  Zhiliang Cheng; Daniel L J Thorek; Andrew Tsourkas
Journal:  Angew Chem Int Ed Engl       Date:  2010       Impact factor: 15.336

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.